Paolo Marolla

544 total citations
16 papers, 322 citations indexed

About

Paolo Marolla is a scholar working on Oncology, Surgery and Hematology. According to data from OpenAlex, Paolo Marolla has authored 16 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 5 papers in Surgery and 4 papers in Hematology. Recurrent topics in Paolo Marolla's work include Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced organ toxicity mitigation (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). Paolo Marolla is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Chemotherapy-induced organ toxicity mitigation (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). Paolo Marolla collaborates with scholars based in Italy, United States and Switzerland. Paolo Marolla's co-authors include Paolo Carlini, Luigi Di Lauro, Diana Giannarelli, E. Terzoli, F. Calabresi, Enrico Cortesi, Mario Nardi, Claudio Botti, Serena Di Cosimo and Cecilia Nisticò and has published in prestigious journals such as Journal of Clinical Oncology, The Oncologist and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Paolo Marolla

15 papers receiving 313 citations

Peers

Paolo Marolla

ONCOL

GENET

PFM

Francesca Conti United States

Ulrike Seitz Germany

Michael W. Potter United States

C. L. Vogel United States

Robert M. Sutphin United States

Carl Högberg Sweden

H.G. Beger Germany

Constantina Sambani Greece

Yiming Shi China

Francesca Conti United States

Paolo Marolla

239 ×1.4

ONCOL

88 ×1.1

141 ×2.0

47 ×1.0

GENET

28 ×0.6

PFM

Citations per year, relative to Paolo Marolla Paolo Marolla (= 1×) peers Francesca Conti

Countries citing papers authored by Paolo Marolla

Since Specialization

Citations

This map shows the geographic impact of Paolo Marolla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paolo Marolla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paolo Marolla more than expected).

Fields of papers citing papers by Paolo Marolla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paolo Marolla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paolo Marolla. The network helps show where Paolo Marolla may publish in the future.

Co-authorship network of co-authors of Paolo Marolla

This figure shows the co-authorship network connecting the top 25 collaborators of Paolo Marolla. A scholar is included among the top collaborators of Paolo Marolla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paolo Marolla. Paolo Marolla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Milella, Michèle, Alain Gelibter, Maria Simona Pino, et al.. (2010). Fixed-Dose-Rate Gemcitabine: A Viable First-Line Treatment Option for Advanced Pancreatic and Biliary Tract Cancer. The Oncologist. 15(2). e1–e4. 6 indexed citations

Malaguti, Paola, Michele Stanislaw Milella, Alain Gelibter, et al.. (2006). Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients. Journal of Clinical Oncology. 24(18_suppl). 14099–14099.

Papaldo, Paola, G. Ferretti, Serena Di Cosimo, et al.. (2006). Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?. Journal of Clinical Oncology. 24(19). 3048–3055. 27 indexed citations

Salesi, Nello, Enzo Veltri, Barbara Di Cocco, et al.. (2005). Clinical experience with bevacizumab in colorectal cancer.. PubMed. 25(5). 3619–23. 12 indexed citations

Papaldo, Paola, Massimo Lopez, Paolo Marolla, et al.. (2005). Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide. Journal of Clinical Oncology. 23(28). 6908–6918. 74 indexed citations

Papaldo, Paola, Massimo Lopez, Enrico Cortesi, et al.. (2003). Addition of Either Lonidamine or Granulocyte Colony-Stimulating Factor Does Not Improve Survival in Early Breast Cancer Patients Treated With High-Dose Epirubicin and Cyclophosphamide. Journal of Clinical Oncology. 21(18). 3462–3468. 65 indexed citations

Nardi, M, et al.. (1996). A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer. Cancer Chemotherapy and Pharmacology. 38(3). 298–301. 4 indexed citations

Calabresi, F., Paolo Marolla, Luigi Di Lauro, et al.. (1994). Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. 4. 753–760. 10 indexed citations

Calabresi, F., Luigi Di Lauro, Paolo Marolla, et al.. (1991). Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.. PubMed. 18(2 Suppl 4). 66–72. 11 indexed citations

10.

Ameglio, Franco, et al.. (1990). Dose and Schedule Effects of Cisplatin on the Related Acute Iron Changes. Oncology. 47(2). 133–138. 3 indexed citations

11.

Boccoli, G, R Masciulli, G. Salvo, et al.. (1990). Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. European Journal of Cancer and Clinical Oncology. 26(11-12). 1152–1156. 47 indexed citations

12.

Nardi, Mario, et al.. (1989). Effective Control of CMF-Related Emesis with High-Dose Dexamethasone. American Journal of Clinical Oncology. 12(6). 524–529. 14 indexed citations

13.

Pollera, C. F., et al.. (1988). Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemotherapy and Pharmacology. 21(1). 61–4. 32 indexed citations

14.

Pollera, C. F., Mario Nardi, Paolo Marolla, & Paolo Carlini. (1987). A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin. Cancer Chemotherapy and Pharmacology. 19(4). 335–8. 3 indexed citations

15.

Taggi, F., Gaetano Vitelli, Paolo Marolla, et al.. (1984). Discriminant analysis of Hodgkin's disease and non-Hodgkin's lymphomas by age and serum proteins. European Journal of Cancer and Clinical Oncology. 20(10). 1243–1247. 4 indexed citations

16.

Lauro, Luigi Di, et al.. (1983). Plasmacytoma of the thyroid gland.. PubMed. 9(1). 61–6. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact